Pages that link to "Q36650783"

The following pages link to Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions (Q36650783):

Displaying 23 items.

• Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide (Q33578853) (← links)
• Adjuvant medical therapy for prostate cancer (Q33758771) (← links)
• Complete estrogen blockade for the treatment of metastatic and early stage breast cancer (Q33955172) (← links)
• Clinical pharmacokinetics of goserelin (Q33991285) (← links)
• Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer (Q34104391) (← links)
• A benefit-risk assessment of medical treatment for uterine leiomyomas (Q34836796) (← links)
• Clinical pharmacokinetics of endocrine agents used in advanced breast cancer (Q35722575) (← links)
• Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women (Q36360338) (← links)
• Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer (Q36972786) (← links)
• Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders (Q36972988) (← links)
• Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders (Q38562059) (← links)
• Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer (Q38574476) (← links)
• Diagnostic value of serum prostate‐specific antigen in hemodialysis patients (Q39647086) (← links)
• Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders (Q40398462) (← links)
• Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty (Q40487158) (← links)
• Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer (Q40627726) (← links)
• Redefining hormone sensitive disease in advanced prostate cancer (Q42593799) (← links)
• Comparative study of different dosages of goserelin in size reduction of myomatous uteri (Q45257788) (← links)
• Development and validation of a micellar electrokinetic capillary chromatography method for the determination of goserelin and related substances. (Q53259999) (← links)
• Pituitary apoplexy after goserelin (Q72540547) (← links)
• Quantification of buserelin in a pharmaceutical product by multiple-injection CZE (Q80189230) (← links)
• Gonadotropin-releasing hormone antagonist in the management of prostate cancer (Q80297643) (← links)
• Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope (Q92257071) (← links)